3Helix has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.

October 20, 2026 2 Min Read

87 0

According to filings with the U.S. Securities and Exchange Commission, 3Helix is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About 3Helix
3Helix, Inc. provides collagen hybridizing peptides (CHPs) for diagnostics and histopathology. Its products support applications including histopathology, mechanical-damage assessment, collagen identification, and cell-invasion research. The company offers fluorescent and biotin-conjugated CHPs, including products designed for in vivo use. 3Helix positions its technology as an established collagen-targeting solution, noting that its CHPs have been cited more than 260 times. The company is based in Salt Lake City, Utah, and its homepage also highlights the launch of BASFs NeoHelix Regenerate product.

To learn more, visit https://www.3helix.com/
LinkedIn: https://www.linkedin.com/company/3helix-inc/

Contact:
Michael Kirkness, Chief Executive Officer
https://www.linkedin.com/in/mike-kirkness/